Abstracts tagged "dermatomyositis"

Abstract Number: 1222 • ACR Convergence 2023
The Association Between Gingival Inflammation and Clinical Signs of Active Juvenile Dermatomyositis (JDM)
Albert Chow¹, Hyun Song², Laurie Brenchley³, Nastaran Bayat⁴, Mary Eckert⁵, Sean Koester⁶, adam Schiffenbauer⁷, Rita Volochayev⁷, Pamela Gardner³, Peggy Lee⁸, Jeffrey McLean⁹, Susan Shenoi¹⁰, Lisa Rider¹¹, Anne Stevens¹² and Neelendu Dey¹³, ¹Loma Linda University, Loma Linda, CA, ²Department of Dentistry, Seattle Children's Hospital, Seattle, WA, ³Office of the Clinical Director, NIDCR, National Institutes of Health, Bethesda, MD, ⁴Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, ⁵Center for Clinical and Translational Research, Seattle Children’s Research Institute, Seattle, WA, ⁶Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁸Department of Oral Medicine, School of Dentistry, University of Washington, Seattle, WA, ⁹Department of Periodontics, University of Washington, Seattle, WA, ¹⁰Seattle Childrens Hospital, Mercer Island, WA, ¹¹NIEHS, NIH, Bethesda, MD, ¹²Janssen, Hansville, WA, ¹³Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, WA
Background/Purpose: JDM is a rare vasculopathy of unknown etiology characterized by typical rashes and proximal weakness. JDM has been associated with gingivitis, which can be…
Abstract Number: 1962 • ACR Convergence 2023
Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis
Yin Wu¹, Aditee Deshpande¹, Nicholas Geraci¹, Vera Sellers², Phanindra Velisetty², David Fiorentino³, Kavita Y. Sarin³ and Andrew Bender¹, ¹Research Unit – Neurology and Immunology, EMD Serono, Billerica, MA, ²Discovery Technologies, EMD Serono, Billerica, MA, ³Department of Dermatology, Stanford University, Redwood City, CA
Background/Purpose: Tissue inflammation is a major disease driver in idiopathic inflammatory myopathies (IIM), leading to muscle weakness and, in the case of dermatomyositis (DM), a…
Abstract Number: 0748 • ACR Convergence 2023
Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT
Kastriot Kastrati¹, Thomas S Nakuz², Oana C Kulterer², Stephan Blüml³, Michael Bonelli³, Irina Gessl⁴, Hans-Peter Kiener³, Werner Langsteger², Daniel Mrak³, Florian Prayer⁵, Helmut Prosch⁵, Elisabeth Simader³, Tatjana Traub-Weidinger², Daniel Aletaha⁶, Helga Radner⁷, Marcus Hacker² and Peter Mandl³, ¹Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, ²Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ⁷Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) ranging up to 78% in IIM and is a key contributor…
Abstract Number: 1230 • ACR Convergence 2023
Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive
Nicholas McClellan, Sarah Vandenbergen, Sophia Matossian, J. Michelle Kahlenberg and Jessica Turnier, University of Michigan, Ann Arbor, MI
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by multiorgan vasculopathy, and degree of vasculopathy can indicate more severe disease. Nailfold capillaroscopy is a non-invasive method to…
Abstract Number: 1964 • ACR Convergence 2023
Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization
Jacob Colello¹, Kirsten Riggle¹, Galen Foulke², Peri Newman¹, Jamie Carter¹ and Nancy Olsen¹, ¹TE-Penn State MS Hershey Medical Center, Hershey, PA, ²Penn State MS Hershey Medical Center, Hershey, PA
Background/Purpose: Dermatomyositis (DM) is a relatively rare condition with significant morbidity and mortality across the lifespan.Recent advances in diagnostics and therapeutics have significant potential to…
Abstract Number: 086 • 2023 Pediatric Rheumatology Symposium
Systemic Sclerosis Overlap Syndrome: A Case Series from a Single Large Pediatric Center
Jessica Nguyen¹, Miriah Gillispie-Taylor¹, Eyal Muscal¹ and Marietta Deguzman², ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Childhood-onset systemic sclerosis (SSc) is a rare but potentially life-threatening autoimmune condition with features including immune, fibrotic, and vascular manifestations affecting the skin and…
Abstract Number: 099 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Juvenile Dermatomyositis
Tresa Ambooken¹, Sangati Kadakia¹, Tara Lozy¹, Brianna Bulbin², Suhas Ganguli³, Dawn Wahezi⁴ and Sivia Lapidus¹, ¹Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Hackensack Meridian School of Medicine, Hackensack, NJ, ³Department of Pediatrics, K. Hovnanian Children's Hospital, Jersey Shore University Medical Center, Neptune City, NJ, ⁴Children's Hospital at Montefiore, New York, NY
Background/Purpose: Juvenile Dermatomyositis (JDM) is theorized to occur in a genetically susceptible individual as a response to an environmental trigger, leading to autoimmunity and inflammation.…
Abstract Number: 100 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): II – A Longitudinal Assessment of Muscle Strength by Manual Muscle Test (MMT) and Childhood Myositis Assessment Scale (CMAS) Tools
Darcisio Antonio¹, Taciana Fernandes¹, Adriana Elias², Teresa Robazzi³, Ana Julia Moraes⁴, Sheila Oliveira⁵, Flavio Sztajnbok⁶, Luciana Carvalho⁷, Luciana Marques⁸, Silvana Sacchetti⁹, Maria Teresa Terreri¹⁰, Simone Appenzelle¹¹, Roberto Marini¹², Carlos Rabello Jr¹³, Cristina Magalhaes¹⁴, Melissa Fraga¹⁵, Marcia Bandeira¹⁶, Iloite Scheibel¹⁷, Isabela Daud², Beatriz Carneiro², Claudio Len¹⁸, Clovis Silva¹⁹ and Claudia Magalhaes²⁰, ¹Universidade Estadual Paulista (UNESP) Botucatu, Brazil, ²Instituto da Criança - Universidade de São Paulo (USP), São Paulo, Brazil, ³Universidade Federal da Bahia, Brazil, ⁴Universidade Federal do Para, Brazil, ⁵Universidade Federal do Rio de janeiro, Rio de Janeiro, ⁶Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁷Universidade de Sao Paulo- Ribeirao Preto, São Paulo, Brazil, ⁸Hospital Albert Sabin, Brazil, ⁹Santa Casa de Sao Paulo, Brazil, ¹⁰UNIFESP, São Paulo, Brazil, ¹¹University of Campinas, Campinas, Sao Paulo, Brazil, ¹²UNICAMP, São Paulo, Brazil, ¹³Hospital Geral de Fortaleza, Brazil, ¹⁴Hospital Jose de Alencar - Brasilia, Brazil, ¹⁵Hospital Darcy Vargas, Brazil, ¹⁶Hospital Pequeno Principe- Curitiba, Brazil, ¹⁷Hospital Conceição de Porto Alegre, Brazil, ¹⁸Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, ¹⁹Universidade de São Paulo, São Paulo, Brazil, ²⁰São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil
Background/Purpose: Muscle weakness is often progressive and persistent in Juvenile Dermatomyositis (JDM). Muscle strength testing is useful for evaluating severity of muscle weakness. There is…
Abstract Number: 101 • 2023 Pediatric Rheumatology Symposium
Differences in Clinical and Patient-reported Outcomes in Juvenile Dermatomyositis by Race and Ethnicity
Susan Kim¹, Rebecca Olveda² and Jessica Neely², ¹UCSF Benioff Children's Hospital, San Francisco, CA, ²UCSF, San Francisco, CA
Background/Purpose: Previous studies in juvenile dermatomyositis (JDM) have shown that patients from minoritized ethnicities and those with lower family income are more likely to have…
Abstract Number: 120 • 2023 Pediatric Rheumatology Symposium
The Brazilian Registry of Juvenile Dermatomyositis (JDM): I- Onset Clinical Features and Disease Activity Scores by DAS-20 over 2-Years-Follow Up
Beatriz Carneiro¹, Adriana Elias¹, Teresa Robazzi², Ana Julia Moraes³, Sheila Oliveira⁴, Flavio Sztajnbok⁵, Luciana Carvalho⁶, Luciana Marques⁷, Silvana Sacchetti⁸, Maria Teresa Terreri⁹, Simone Appenzelle¹⁰, Roberto Marini¹¹, Andre Cavalcante¹², Marcia Bandeira¹³, Cristina Magalhaes¹⁴, Melissa Fraga¹⁵, Iloite Scheibel¹⁶, Isabela Daud¹, Darcisio Antonio¹⁷, Claudio Len¹⁸, Clovis Silva¹⁹, Taciana Fernandes¹⁷ and Claudia Magalhaes²⁰, ¹Instituto da Criança - Universidade de São Paulo (USP), São Paulo, Brazil, ²Universidade Federal da Bahia, Brazil, ³Universidade Federal do Para, Brazil, ⁴Universidade Federal do Rio de janeiro, Rio de Janeiro, ⁵Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁶Universidade de Sao Paulo- Ribeirao Preto, São Paulo, Brazil, ⁷Hospital Albert Sabin, Brazil, ⁸Santa Casa de Sao Paulo, Brazil, ⁹UNIFESP, São Paulo, Brazil, ¹⁰University of Campinas, Campinas, Sao Paulo, Brazil, ¹¹UNICAMP, São Paulo, Brazil, ¹²Hospital Materno-Infantil de Goiania, Brazil, ¹³Hospital Pequeno Principe- Curitiba, Brazil, ¹⁴Hospital Jose de Alencar - Brasilia, Brazil, ¹⁵Hospital Darcy Vargas, Brazil, ¹⁶Hospital Conceição de Porto Alegre, Brazil, ¹⁷Universidade Estadual Paulista (UNESP) Botucatu, Brazil, ¹⁸Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, ¹⁹Universidade de São Paulo, São Paulo, Brazil, ²⁰São Paulo State University, Pediatric Rheumatology Division, Botucatu, Brazil
Background/Purpose: A national registry was set up, enrolling new onset JDM cases in 18 hospitals, during 3-years (2015-2018) with 2-years follow up, in a low…
Abstract Number: 004 • 2023 Pediatric Rheumatology Symposium
Analysis of Patients with Juvenile Dermatomyositis Compared to Healthy Controls Using CITE-seq Identifies Differences in Cell Composition and Gene and Epitope Expression
Camilla Wibrand¹, Emily Flynn², Gabrielle Rabadam², George Hartoularos², Yang Sun², Chun Ye², Susan Kim³, Marina Sirota² and Jessica Neely¹, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare and serious systemic autoimmune condition, and much remains unknown about the pathogenesis, the immune cell types and cell-specific…
Abstract Number: 008 • 2023 Pediatric Rheumatology Symposium
Treatment Response and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis
Belina Yi¹, Dawn Wahezi², Lauren Covert³, Kaveh Ardalan⁴, Joyce Hui-Yuen⁵, Natalia Vasquez Canizares², Doaa Mosad Mosa⁶, Madison Jones⁷, Colleen Correll⁸, Alexis Begezda⁹, Susan Shenoi¹⁰, Eveline Wu¹¹, Leonard Kovalick¹², William Lapin¹³, Stacey Tarvin¹⁴, Melissa Oliver¹⁵, Martha Rodriguez¹⁴, Itay Marmor¹⁶, Kevin Baszis¹⁷, Alysha Taxter¹⁸, Andrew Hanson¹⁹, Cynthia Crowson¹⁹ and Amir Orandi¹⁹, ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital at Montefiore, New York, NY, ³Duke University, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵Cohen Children's Medical Center, Northwell Health, Lake Success, New York; Center for Autoimmune, Musculoskeletal, and Hematopoietic Diseases Research, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, ⁶Mansoura University Hospitals, Mansoura University Faculty of Medicine, El Mansoura, Egypt, ⁷Keck School of Medicine at University of Southern California, Los Angeles, CCA, ⁸University of Minnesota, Minneapolis, MN, ⁹Penn State, State College, PA, ¹⁰Seattle Children's Hospital, Seattle, WA, ¹¹UNC Chapel Hill, Chapel Hill, NC, ¹²UNC Health Care, Durham, NC, ¹³Connecticut Children's, Hartford, CT, ¹⁴Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ¹⁵Indiana University, Indianapolis, IN, ¹⁶Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ¹⁷Washington University School of Medicine, St Louis, MO, ¹⁸Nationwide Children's Hospital, Columbus, OH, ¹⁹Mayo Clinic, Rochester, MN
Background/Purpose: Calcinosis is a poorly understood and morbid complication of juvenile dermatomyositis (JDM). As there is no consensus treatment approach for calcinosis, and limited knowledge…
Abstract Number: 018 • 2023 Pediatric Rheumatology Symposium
Using the Electronic Health Record to Identify Subjects with Rheumatic Disease
Alysha Taxter¹, Matthew Basiaga², Rajdeep Pooni³, Caitlan Pinotti⁴, Lisa Buckley⁵ and CARRA Registry Investigators⁶, ¹Nationwide Children's Hospital, Columbus, OH, ²Mayo Clinic, Rochester, MN, ³Stanford University, Palo Alto, CA, ⁴Duke, Durham, NC, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶CARRA, Washington, DC
Background/Purpose: Research teams spend hours manually searching the electronic health records (EHRs) to identify potential candidates eligible for recruitment to the Childhood Arthritis and Rheumatology…
Abstract Number: 023 • 2023 Pediatric Rheumatology Symposium
Effect of Type 1 Interferons and JAK Inhibitors on Gene Expression in Bioengineered Pediatric Skeletal Muscle
Lauren Covert¹, Joseph Prinz², Hailee Patel³, Jeffrey Dvergsten⁴ and George Truskey³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Department of Biostatistics and Bioinformatics, Durham, NC, ³Duke University, Department of Biomedical Engineering, Durham, NC, ⁴Duke University Hospital, Durham, NC
Background/Purpose: Genetic studies of new-onset juvenile dermatomyositis (JDM) exhibit elevation of Type 1 interferons (IFN 1) IFNα and IFNβ in blood, skin, and muscle. To…
Abstract Number: 027 • 2023 Pediatric Rheumatology Symposium
Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa
Jessica Perfetto¹, Laura Lewandowski², Dawn Wahezi¹, Christiaan Scott³ and Angela Migowa⁴, ¹Children's Hospital at Montefiore, New York, NY, ²NIAMS, NIH, Bethesda, MD, ³Red Cross War Memorial Children's Hospital, ⁴Aga Khan University, Nairobi, Kenya
Background/Purpose: There is a paucity of data on pediatric rheumatic disease (PRD) in low and middle-income countries (LMIC), creating a false perception of low prevalence…

« Previous Page
1
…
6
7
8
9
10
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].